Compare Deckers Outdoor Corp (DECK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Summit Therapeutics Inc — how do they compare? Deckers Outdoor Corp trades at $82.95 (market cap $11.24B), while Summit Therapeutics Inc trades at $17.38 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Summit Therapeutics Inc for 16 Days on average.
| DECK | SMMT | |
|---|---|---|
Market Cap | $11.24B | $13.71B |
Volume | 3,010,945 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $26.38 |
52-Week Low | $77.51 | $12.43 |
Typical Hold Time | 71 Days | 16 Days |
Enterprise Value | $10.11B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DECK trades at $80.38, down 1.57% on the day, with a neutral technical signal and strong fundamentals. Revenue grew to $4.99B in 2025, net income reached $966.09M, and profitability metrics like ROE of 42.56% are robust. Recent earnings beats and analyst upgrades reflect optimism, while cash flow trends show operational strength despite a projected net outflow in 2026.
The outlook is positive given valuation discounts (P/E 11.74), consistent earnings outperformance, and bullish analyst targets averaging $117.13. Risks include reliance on key brands HOKA and UGG, competitive pressures, and potential macroeconomic headwinds affecting consumer discretionary spending.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
